HCV Induced Liver Disease
HCV Viral Load
- Hep 05
- Hep 01
- Hep 04
- Hep 03
- Hep 07
- Hep 06
- Hep 02
- Hep 09
- Hep 010
- Hep 05
- Hep 01
- Hep 04
- Hep 03
- Hep 07
- Hep 06
- Hep 02
- Hep 09
- Hep 010
HCV viral load before and after infusion of Stem Cells (IU/ml).
Nine liver disease study pilot patients showing reduction in viral load over 3 month study period
Hepatitis C is caused by an infection with the hepatitis C virus (HCV) and leads to liver inflammation. The World Health Organisation estimates that about 3% of the world’s population has been infected with HCV, and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer (HCC: hepatocellular carcinoma) later in life.
Chronic liver disease in Egypt is recognised as a serious health problem with about 18% of the population, or 13.9 million people, with liver disease, three quarters of whom test positive for HCV. In Egypt since most infections were transmitted between 25 and 40 years ago, HCV cases tend to be advanced, longstanding infections with many progressing to end-stage liver disease.
TriStem’s clinical study
The Egyptian Society for Stem Cell Therapy is currently conducting a study in 60 patients with HCV-induced liver disease. Patients will receive stem cells created from their own white blood cells. Over a 12 month follow up period, various liver function tests will be carried out to determine if the liver damage has been reversed. This study is being conducted in accordance with international clinical trial regulations and is being lead by Dr Hosny Salama.
The results are expected to be available in 2017.